#USA #Boston #electrophysiology #Haemonetics #VASCADE MVP

Introduction

In an emerging field of medical technology, Haemonetics Corporation recently unveiled a pivotal study showcasing the efficacy of their VASCADE MVP® XL venous vascular closure system. As the demand for innovative medical solutions increases, this extensive research demonstrates remarkable outcomes in electrophysiology procedures, particularly those involving large-bore sheaths. The study, which is the largest reported cohort to date, provides substantial evidence geared towards improving patient outcomes and experience.

Study Overview

Conducted at Emory University with funding from Haemonetics, this retrospective cohort study evaluated 1,623 patients who underwent a variety of electrophysiology procedures using the VASCADE MVP XL system. These procedures included pulsed field ablation (PFA) for atrial fibrillation, left atrial appendage closure, and other related treatments requiring sheaths of up to 17F in outer diameter. The results are compelling, illustrating rapid rates of hemostasis, favorable discharge statistics, and a low incidence of complications.

Significant Findings

The data revealed several key outcomes:

• - Rapid Hemostasis: The VASCADE MVP XL system achieved a median time for hemostasis of just 2 minutes.
• - Same-Day Discharge: An impressive 92.5% of patients were discharged on the same day, with a median discharge time of 3.5 hours post-procedure.
• - Safety Profile: The overall rate of vascular complications stood at a mere 1.2%, and notably, no surgical interventions were necessary in these cases.

According to Ken Crowley, Haemonetics' Vice President and General Manager of Interventional Technologies, these results reinforce the consistent performance of the VASCADE MVP XL in ensuring safe and effective venous closure, thereby enhancing patient care in electrophysiology settings.

Expert Insights

The study's lead author, Dr. David B. De Lurgio, who serves as the Medical Director of Electrophysiology at Emory Saint Joseph's Hospital, emphasized the importance of these findings. He noted, "What stands out is the consistent achievement of same-day discharge, even for sheaths larger than previously utilized in device-based closure. This study provides real-world evidence that is comprehensive, considering a wide range of patients and procedures, including those with heightened comorbid conditions."

Regulatory Approval

In a noteworthy development, the U.S. Food and Drug Administration (FDA) recently approved an expanded labeling for the VASCADE MVP XL system. This now includes usage with inner diameter sheaths ranging from 10F to 14F, up to a maximum outer diameter of 17F. This rating expands the scope of procedures the system can safely accommodate, thereby increasing its utility in various clinical environments.

The FDA's decision was backed by clinical evidence from the AMBULATE EXPAND trial, which underscored the system’s ability to achieve rapid hemostasis without complications, thus facilitating same-day discharge for patients.

Conclusion

Haemonetics Corporation's strides in medical technology, evidenced by the VASCADE MVP XL venous vascular closure system, signal positive advancements in electrophysiological procedures. With significant research outcomes promoting the system's safety and efficacy, clinicians are now equipped with an advanced tool to positively impact patient care. As healthcare continues to evolve towards more patient-centered solutions, the VASCADE MVP XL stands out as a crucial advancement for practitioners and patients alike. For more information about Haemonetics and their innovative products, visit Haemonetics' website.